Company Directory / research

A2 Biotherapeutics logo

PrivateFor profitresearchAgoura Hills, United States

A2 Biotherapeutics

A2 Biotherapeutics is an early-stage biotechnology company that develops medicines for serious illnesses.

Founded
2018
8 years ago
Staff
51-100
band, as listed
Followers
-
on LinkedIn
Funding
$191M
as listed, currency not stated

Set against six million companies

Size

1-1011-5051-100101-250251-500501-10001k-5k5k-10k10k+

51-100 people: larger than 75% of companies with a size listed

Age

201819002026

8 years old.

Reach

No web traffic ranking listed.

What it does

BiotechnologyHealth CareLife Science

Funding, as listed

$191M currency not stated

  • Rounds4
  • LatestSeries b, Dec 2022
  • Investors8

What the source datasets report. We have not watched these rounds ourselves.

FoundersAlexander Kamb

Every detail we hold

Everything the source datasets list about A2 Biotherapeutics, field by field. Contact details are held but never shown.

The company

Name
A2 Biotherapeutics
Type
For profit
Status
Private
Founded
2018
Founders
Alexander Kamb
Industry
research
Categories
Biotechnology, Health Care, Life Science

Where

City
Agoura Hills
Country
United States
Markets
Greater Los Angeles Area, West Coast, Western US

Size and reach

Staff band
51-100

Funding, as listed

Total
190,500,000 (currency not stated)
Rounds
4
Latest round
Series b
Latest round date
Dec 2022
Investors
8
Listing status
private

About this record

Sources
Crunchbase
Last imported
Sept 2026

Growth, as the source summarises it

A2 Biotherapeutics may be growing as indicated by the company's active participation in the American Society of Clinical Oncology (ASCO) Annual Meeting, where they highlighted the progress of their CAR T clinical programs through three poster presentations. This suggests ongoing research and development efforts, which are critical for growth in the biotechnology industry. Additionally, the mention of a C-Suite shuffle implies organizational changes that could be associated with expansion or scaling efforts. The focus on CAR T-cell clinical programs also indicates a specialization in a cutting-edge area of biotechnology, which could position the company for growth within the health care and life science industries.

Summaries written by the source dataset, not by us, and not checked.

Companies like it

research in United States.

See all in the directory →

From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.